LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

Home・Stock List・Amgen Inc

Amgen Inc

Closed

Sector Healthcare

321.39 -0.06

Buy Sell

Overview

Share price change

24h

Current

Min

320.33

Max

324.88

Key metrics
By Trading Economics
Income	859M 746M
Sales	940M 8.4B
P/E Sector Avg	44.64 112.16
EPS	4.97
Profit margin	8.892
Employees	26,700
EBITDA	847M 3B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+5.99 upside

Dividends
By Dow Jones
Next Earnings	30 Oct 2024
Next Dividend date	6 Dec 2024
Next Ex Dividend date	14 Nov 2024

Market Stats
By TradingEconomics
Market Cap	4.1B 175B
Previous open	321.45
Previous close	321.39

News Sentiment

By Acuity

43%

57%

148 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

319.73 / 322.41 Support & Resistance

Amgen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Aug 2024, 21:00 UTC

Earnings

Amgen 2Q Revenue Jumps, Profit Narrows on Higher Expenses

2 May 2024, 20:42 UTC

Earnings

Amgen Posts Higher 1Q Revenue, Swings to Loss

25 Sept 2024, 16:19 UTC

Top News

Dow Falls, Nasdaq Rises, Chinese Shares Rally -- WSJ

20 Sept 2024, 13:55 UTC

Top News

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

10 Sept 2024, 20:38 UTC

Acquisitions, Mergers, Takeovers

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

10 Sept 2024, 14:42 UTC

Acquisitions, Mergers, Takeovers

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

3 Sept 2024, 04:00 UTC

Top News

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

7 Aug 2024, 14:22 UTC

Top News

Earnings

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7 Aug 2024, 09:07 UTC

Earnings

Hot Stocks

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7 Aug 2024, 08:55 UTC

Top News

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

6 Aug 2024, 20:20 UTC

Earnings

Amgen Sees FY24 Share Repurchases Not Exceeding $500 M >AMGN

6 Aug 2024, 20:20 UTC

Earnings

Amgen Sees FY24 Capital Expenditures About $1.3 B >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen 2Q EPS $1.38 >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen 2Q Adj EPS $4.97 >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen 2Q Worldwide Neulasta Sales $105M >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen 2Q Worldwide Prolia Sales $1.17B >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen Sees FY Adj EPS $19.10-Adj EPS $20.10 >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen 2Q Net $746M >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen 2Q Worldwide XGEVA Sales $562M >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen Sees FY EPS $6.57-EPS $7.62 >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen 2Q Rev $8.4B >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen 2Q Worldwide Enbrel Sales $909M >AMGN

6 Aug 2024, 20:01 UTC

Earnings

Amgen Sees FY Rev $32.8B-$33.8B >AMGN

6 Aug 2024, 08:45 UTC

Top News

Earnings

These Stocks Are Moving the Most Today: Palantir, Nvidia, Apple, Lumen, Lucid, Caterpillar, and More -- Barrons.com

19 Jul 2024, 11:00 UTC

Top News

Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ

19 Jun 2024, 05:30 UTC

Top News

Acquisitions, Mergers, Takeovers

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

3 May 2024, 14:43 UTC

Hot Stocks

Stocks to Watch Friday: Apple, Amgen, Exxon, Coinbase -- WSJ

3 May 2024, 11:43 UTC

Market Talk

Earnings

Amgen's Weight-Loss Drug Prospects Win New Bull -- Market Talk

3 May 2024, 08:45 UTC

Earnings

Hot Stocks

Stocks to Watch Friday: Apple, Amgen, Block -- WSJ

3 May 2024, 08:28 UTC

Earnings

These Stocks Are Moving the Most Today: Apple, Amgen, Expedia, Block, Coinbase, Cloudflare, Fortinet, and More -- Barrons.com

Peer Comparison

Price change

Amgen Inc Forecast

Price Target

By TipRanks

5.99% upside

12 Months Forecast

Average 340.89 USD 5.99%

High 405 USD

Low 215 USD

Based on 22 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

22 ratings

Buy

Hold

Sell

Based on 22 analysts giving stock ratings to Amgen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

319.73 / 322.41Support & Resistance

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

148 / 366 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.